Dicerna Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on the discovery and development of treatments for rare inherited diseases. It offers GalXC, a liver-targeted technology for tissues and cell types, and an RNA interference (RNAi) technology platform. The company also provides a pipeline of RNAi therapies.